Polypeptides-Drug Conjugates for Anticancer Therapy
Polypeptides-Drug Conjugates for Anticancer Therapy
复制标题
用于抗癌治疗的多肽-药物缀合物
DOI：
10.1002/adhm.202001974
复制
发表时间：
2021
影响因子：
10
通讯作者：
Chen Xuesi
中科院分区：
文献类型：
--
作者：
Zhang Yu;He Pan;Zhang Peng;Yi Xuan;Xiao Chunsheng;Chen Xuesi
多肽是一类重要的生物可降解聚合物，在药物释放领域有着广泛的应用。由于可控合成和强大的侧链官能化能力，多肽长期以来一直是与抗癌药物缀合的理想候选物。抗癌药物与多肽的化学偶联，称为多肽-药物偶联物，已经证明在改善药代动力学、增强药物靶向和控制药物释放方面具有若干优点，从而导致增强的治疗结果和降低的副毒性。本文综述了近年来多肽-药物偶联物的设计和制备的研究进展。总结了将不同类型的药物（包括小分子化疗药物、蛋白质、血管破坏剂和气体分子）缀合到多肽主链上的策略。最后，对新型多肽-药物偶联物在肿瘤治疗中的应用前景进行了展望。
Polypeptides are an important class of biodegradable polymers that have been widely used in drug delivery field. Owing to the controllable synthesis and robust side chain‐functionalization ability, polypeptides have long been ideal candidates for conjugation with anticancer drugs. The chemical conjugation of anticancer drugs with polypeptides, termed polypeptides–drug conjugates, has demonstrated several advantages in improving pharmacokinetics, enhancing drug targeting, and controlling drug release, thereby leading to enhanced therapeutic outcomes with reduced side toxicities. This review focuses on the recent advances in the design and preparation of polypeptides–drug conjugates for enhanced anticancer therapy. Strategies for conjugation of different types of drugs, including small‐molecule chemotherapeutic drugs, proteins, vascular disrupting agents, and gas molecules, onto polypeptides backbone are summarized. Finally, the challenges and future perspectives on the development of innovative polypeptides–drug conjugates for clinical cancer treatment are also presented.